Parvus Therapeutics
Suite 119, 3553 31 Street NW
Calgary
Alberta
T2L 2K7
Canada
Tel: 1-403-708-3401
Website: http://www.parvustherapeutics.com/
8 articles about Parvus Therapeutics
-
Parvus Therapeutics Announces Key Executive and Board of Directors Appointments
7/16/2019
Hugh Young Rienhoff, Jr., M.D., appointed as Chairman of the Board Charles A. Johnson, M.D., appointed to Board of Directors Alain Delcayre, Ph.D., appointed Senior Vice President of Research
-
Parvus Therapeutics Publication of Preclinical Proof-of-Concept Research that Underlies the Development of Navacim™ Therapeutics for the Treatment of Autoimmune Liver Diseases
6/26/2019
Research underpins part of the recently executed license and collaboration agreement to develop, manufacture and commercialize Navacim™ therapeutics for treatment of gastrointestinal inflammatory diseases, including autoimmune liver disease
-
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases
5/16/2019
Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales
-
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus' technology to target IBD and Celiac.
-
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
-
Parvus Therapeutics Appoints Dr. Curtis Ruegg as Chief Executive Officer
5/30/2018
Parvus is advancing a therapeutic pipeline of novel class of disease-modifying therapeutics – Navacims™ – toward clinical testing for the treatment of diverse autoimmune diseases
-
Parvus Therapeutics Announces Exclusive Worldwide License And Collaboration Agreement For The Development And Commercialization Of Its Lead Nanomedicine To Treat Type 1 Diabetes
4/19/2017
-
Parvus Therapeutics ' Nanotechnology Treatment Reprograms Immune Cells To Reverse Autoimmune Disease, As Published In Nature
2/18/2016